Estudio Comparativo entre Terapia con Melissa officinalis vs. Tratamiento Convencional con Aciclovir Tópico al 5% para Lesiones Herpéticas Tipo 1 / Comparative Study of Therapy with Melissa Officinalis vs. Conventional Topical Treatment with 5% Acyclovir in Type 1 Herpes Lesions

El herpes simple tipo I es una patología infecciosa e inflamatoria de tipo vírico que se caracteriza por la aparición de lesiones ulcerativas extra orales, de duración aproximada de 14 días y que provocan gran picazón e incomodidad a las personas que lo padecen. El objetivo de este trabajo fue evaluar el uso la Melissa officinalis (toronjil) como terapia alternativa sobre el tiempo de remisión y el número de las lesiones extraorales en pacientes con herpes simple del comparado con el Aciclovir tópico al 5% como terapia convencional. Se realizó un ensayo clínico, aleatorizado y enmascarado simple, controlado. Se evaluó a 34 pacientes con lesiones herpéticas extra orales activas en la etapa primaria vesiculosa, sin patologías asociadas a alteraciones del sistema inmunológico como diabetes mellitus, alergias e hipertensión arterial. Se les administró el tratamiento tópico y se les evalúo diariamente las lesiones herpéticas. La Melissa officinalis posee un efecto antiviral sobre lesiones herpéticas tipo 1 al igual que el Aciclovir tópico al 5%, pero la Melissa officinalis es más efectivo en la disminución de días con lesiones herpéticas (valor p=0,05). La Melissa officinalis tiene un efecto antiviral positivo sobre lesiones herpéticas tipo 1, disminuyendo el número total de días con las lesiones herpéticas en comparación con el Aciclovir tópico al 5%.

Herpes simplex type I is an infectious viral and inflammatory disease type which is characterized by the appearance of extra- oral ulcerative lesions of approximately 14 days that cause severe itching and discomfort for those who have the lesions. The objective of this study was to evaluate the use of Melissa officinalis (lemon balm) as an alternative therapy on remission time and the number of extra oral lesions in patients with herpes simplex compared with topical 5% acyclovir and conventional therapy. A clinical, randomized and single-blind, controlled trial study was carried out. Thirty-four patients were evaluated with active extra- oral herpetic vesicular lesions in primary stage, without pathologies associated with immune system disorders such as diabetes mellitus, allergies and hypertension. They were given topical treatment and herpetic lesions were evaluated daily. Melissa officinalis has an antiviral effect on type 1 herpes lesions as 5% topical acyclovir, Melissa officinalis but is more effective in the reduction of days with herpetic lesions (p value <0.05). In conclusion, Melissa officinalis has a positive antiviral effect on type 1 herpes lesions, reducing the total number of days with herpetic lesions compared with topical 5% acyclovir.

Caulerpin as a potential antiviral drug against herpes simplex virus type 1

About 80% of the human adult population is infected with HSV-1. Although there are many anti-HSV-1 drugs available (acyclovir, ganciclovir, valaciclovir, foscarnet), their continuous use promotes the selection of resistant strains, mainly in ACV patients. In addition to resistance, the drugs also have toxicity, particularly when administration is prolonged. The study of new molecules isolated from green algae with potential antiviral activity represents a good opportunity for the development of antiviral drugs. Caulerpin, the major product from the marine algae Caulerpa Lamouroux (Caulerpales), is known for its biological activities such as antioxidant, antifungal, acetylcholinesterase inhibitor (AChE) and antibacterial activity. In this work, we show that caulerpin could be an alternative to acyclovir as an anti-HSV-1 drug that inhibits the alpha and beta phases of the replication cycle.

Recurrent herpes simplex infections: laser therapy as a potential tool for long-term successful treatment / Herpes simplex recorrente: laser terapia como método alternativo para tratamento a longo prazo

Herpes simplex virus types 1 and 2 are the main infectious agents associated with oral and genital ulcerations. These infections are now widely recognized as sexually transmitted diseases. Among treatment options, low-level laser therapy (LLLT) has shown promising clinical results as a longer-lasting suppression therapy. Two clinical cases are described with recurrent labial herpes for which LLLT was used. Following treatment, both patients remained symptom free during the 17-month clinical follow-up period.

Os vírus do herpes simplex tipos 1 e 2 são os principais agentes infecciosos associados às ulcerações orais e vaginais. Estas infecções são amplamente reconhecidas como doenças sexualmente transmissíveis. Entre as opções de tratamento, o laser de baixa intensidade (LBI) mostrou resultados promissores como terapia de supressão de longa duração. Descrevemos dois casos clínicos com herpes labial recorrentes nos quais o LBI foi utilizado que permaneceram assintomáticos durante 17 meses de controle clínico.

Impacto do laser de baixa intensidade na supressão de infecções pelos vírus Herpes simplex 1 e 2: estudo in vitro / Impact of low-intensity laser on the suppression of infections caused by Herpes simplex viruses 1 and 2: in vitro study

O uso do laser de baixa intensidade na supressão de infecções pelos vírus Herpes simplex 1 e 2 foi avaliado após uma a cinco aplicações, sendo observada uma redução gradual na replicação dos vírus Herpes simplex 1 e 2 com 68,4 por cento e 57,3 por cento de inibição, respectivamente, após 5 aplicações, indicando o seu uso clínico.

The use of low-level laser to suppress infections caused by Herpes simplex viruses 1 and 2 was evaluated after one to five applications. A gradual reduction in replication of Herpes simplex viruses 1 and 2 was observed, with 68.4 percent and 57.3 percent inhibition, respectively, after five applications, thus favoring its clinical use.